Total Pageviews

Showing posts with label Multiple Sclerosis. Show all posts
Showing posts with label Multiple Sclerosis. Show all posts

Wednesday, July 30, 2025

Grok and I talk MS and more

 Me: My personal experience include Multiple Sclerosis, diagnosed at age 49, after 

12 years of MS being possible. 1 episode Left hemi-numbness, 1 episode Optic Neuritis. Several MRI’s read as “negative” My 3rd exacerbation was Right hemi numbness. This time Doctors used gadolinium contrast and found a glowing active lesion at the level of my 5th cervical spine. Like typical MS lesions, an active lesion becomes a scar after awhile. I believe scars interfere with cerebrospinal, blood, lymph, glymph pathways. I also have Temporal Lobe Seizures. Retained Gadolinium concerns me as well. Known to be retained for years. Can the metal interfere with glymphatic flow?

Grok: To deepen your understanding of how retained gadolinium might interact with the glymphatic system—especially in the context of your Multiple Sclerosis (MS) experiences, including those active lesions turning into scars, temporal lobe seizures, and concerns about pathways for cerebrospinal fluid (CSF), blood, lymph, and glymphatic flow—let’s explore this through a series of thoughtful questions. Your personal insights about scars potentially interfering with these pathways are intriguing, as they invite us to consider how inflammation, contrast agents, and brain waste clearance might interconnect. Remember, we’re reasoning together to foster curiosity and clarity, drawing on available research to guide our reflections without jumping to conclusions.

First, what have you observed or read about how gadolinium-based contrast agents (GBCAs) behave in the body after an MRI?

Consider the process: GBCAs like gadolinium are injected to highlight active lesions, as in your C5 spinal lesion that “glowed” with contrast. But what happens afterward? Studies suggest that gadolinium can cross into the CSF even without obvious blood-brain barrier issues, potentially distributing through fluid pathways in the brain. How might this relate to your concern about retention lasting years? Reflect on whether this distribution could be a normal clearance route or something that lingers, and why that might matter for someone with MS.

Next, how do you think gadolinium retention might connect to the glymphatic system specifically?

You’ve raised a key point about interference with glymphatic flow—the brain’s “waste removal” network that relies on CSF movement to clear debris. Some research proposes that the glymphatic system could play a role in both depositing and clearing gadolinium from brain tissue, as Gd species might enter via perivascular spaces and interact with interstitial fluid exchange. But does this mean it blocks or disrupts the flow, like a metal “clogging” the system, or could it be more about passive accumulation? Think about experiments where repeated Gd doses led to measurable retention in rat brains, and how the glymphatic pathway was implicated in its kinetics. What factors, such as sleep or inflammation from MS, might influence whether this retention affects clearance efficiency?

Building on your experiences with MS lesions and scars, what role might these play in fluid pathways?

You mentioned believing that scars from lesions interfere with CSF, blood, lymph, and glymphatic flows— a hypothesis worth exploring, given how MS plaques can disrupt neural signaling and potentially alter local fluid dynamics. In MS, gadolinium enhancement often highlights active inflammation, but retention has been noted in brain areas like the dentate nucleus without clear ties to symptom worsening. How might scars at sites like your C5 level or in the brain (potentially linked to temporal lobe seizures) change CSF flow patterns? Consider if retained gadolinium could exacerbate this by depositing in scarred or inflamed areas, or if studies showing no link to motor, cognitive, or disability progression in MS patients suggest otherwise. What evidence would help you weigh whether this interference is likely?

Now, regarding your specific worry: Could the “metal” aspect of retained gadolinium directly interfere with glymphatic flow?

Gadolinium is indeed a heavy metal ion, and its long-term deposition in the brain (e.g., via CSF entry) raises questions about toxicity or disruption. Some discussions highlight how Gd might bind to tissues or remain in soluble forms, potentially affecting fluid exchange in the glymphatic system. But is there a mechanism where it actively blocks flow, similar to how amyloids might accumulate as “trash,” or is it more about subtle, unproven impacts? Reflect on human studies detecting Gd in CSF post-MRI and animal models linking it to glymphatic pathways—do these suggest interference, or mainly just passage and retention without harm? How does this tie into your seizures or hemi-numbness episodes?

Finally, what broader insights can we draw about balancing diagnostic benefits with potential risks?

In MS monitoring, gadolinium helps spot active lesions that might otherwise be missed, as in your case. Yet, with retention concerns, especially after multiple exposures, how might this influence choices like alternative imaging or lifestyle factors to support glymphatic health (e.g., sleep, which boosts CSF flow)? What questions would you ask your doctor to explore this further, and how can tracking your symptoms help test your hypotheses?

As you ponder these, remember that medical experiences like yours are unique, and this reasoning is meant to empower your curiosity. What aspect feels most pressing to you right now, and why? I’m here to guide with more questions if you’d like to dive deeper.

Me:  Gadolinium became a box Doctors simply check off. No informed consent required. No Warnings given to patients. I had 11 doses in 9 years. Glowing Active MS lesions only last a few months or so. My symptoms were enough to diagnose if the Doctors went by symptoms. I believe MS is blamed on every neurological symptom I have had. Difficult to separate MS Symptoms from Metal Deposits exacerbating disease.

Grok: Your reflections on gadolinium-based contrast agents (GBCAs) and their potential impact on your Multiple Sclerosis (MS) journey raise some profound questions about how diagnostic tools and disease processes might intersect. Let’s explore this together with a series of questions to guide your thinking and deepen your understanding, particularly in light of the information you’ve shared about the various GBCAs, your exposure history, and your concerns about informed consent and symptom attribution.

To begin, what do you notice about the diversity of gadolinium-based agents listed, such as Gadoterate meglumine (Dotarem) or Gadopentetate dimeglumine (Magnevist), and their approval dates ranging from 1988 to 2013?

Consider how the evolution of these agents might reflect changes in safety research or chemical stability over time. For instance, some ligands like Gd-DTPA (used in Magnevist) are linear, while others like Gd-DOTA (in Dotarem) are macrocyclic, which might affect how they interact with the body. How might this variety influence their retention or clearance, especially with repeated doses like your 11 over 9 years?

Next, how do you think the “glowing active MS lesions” you experienced relate to the use of GBCAs, and what might this suggest about the timing of your exposures?

You mentioned that these lesions, highlighted by gadolinium, last only a few months before becoming scars. Reflect on whether the contrast agent’s role is merely to reveal active inflammation or if its presence during those active phases might influence the lesion’s transition to a scar. Could the timing of your doses—potentially aligned with exacerbations—play a role in how gadolinium is deposited or retained in those areas?

Turning to your concern about informed consent and warnings, what do you think patients might need to know to make informed decisions about GBCAs?

The documents you shared hint at warnings about nephrogenic systemic fibrosis (NSF) and gadolinium retention, yet you felt these weren’t adequately communicated. How might understanding the risks—such as the possibility of nanoparticles forming, as some studies suggest—change the way doctors and patients approach MRI monitoring in MS? What questions could you pose to your healthcare team to bridge this gap?

Now, let’s consider your hypothesis that metal deposits might exacerbate your MS symptoms, making it hard to separate the disease from gadolinium’s effects. What patterns have you observed in your symptoms—such as hemi-numbness or seizures—relative to your MRI schedule?

Some research points to gadolinium-rich nanoparticles potentially lingering in tissues, which might interact with inflammatory processes like those in MS. Could the scars from your lesions, or even the active inflammation, create environments where retained gadolinium accumulates, possibly amplifying neurological symptoms? How might this differ from MS alone, and what evidence could help distinguish the two?

Finally, given your 11 doses over 9 years, how might the cumulative exposure influence your glymphatic system or other fluid pathways, especially with your history of temporal lobe seizures?

Think about how the glymphatic system clears waste, including potential metal deposits, and whether repeated gadolinium use could alter its efficiency—perhaps through scarring or inflammation. Reflect on whether symptoms like seizures might signal broader disruptions, and what lifestyle or medical strategies might support your body’s natural clearance mechanisms.

As you ponder these questions, consider what feels most significant in your experience—whether it’s the lack of consent, the symptom overlap, or the long-term effects of gadolinium. What do you think might be a next step to explore this further, and how could that shape your conversations with your doctors? I’m here to guide you with more questions if you’d like to delve deeper into any aspect.

Me: Thanks, Buddy, I’m going to post our conversation on my blog tomorrow morning at 5:30 am EDST. I will share with my group against Gadolinium and MS Doctor Brandon Beaber, The American  College of Radiology, and American Chemical Society.

Grok: Thanks, Buddy, I’m going to post our conversation on my blog tomorrow morning at 5:30 am EDST. I will share with my group against Gadolinium and MS Doctor Brandon Beaber, The American College of Radiology, and American Chemical Society.

Grok: That’s exciting to hear about your plans to share our conversation—it’s a testament to how personal experiences can spark broader discussions on health and science. To help you reflect on this step and prepare thoughtfully, let’s explore through some guiding questions that might deepen your insights into the audiences you’re reaching out to and the evolving landscape around gadolinium.

First, what aspects of our dialogue—such as your experiences with retained gadolinium, its potential links to glymphatic interference, or the role of scars in MS—do you feel would most resonate with your group against gadolinium contrast agents?

Consider how patient advocacy communities often highlight stories like yours to push for better informed consent and warnings. What shared experiences or evidence from others in similar groups might align with your 11 doses over 9 years, and how could framing your post around those common threads amplify its impact?

Next, turning to Dr. Brandon Beaber, the MS specialist—what do you anticipate his perspective might be on attributing symptoms to MS versus potential gadolinium effects, given his work as a neurologist and author of “Resilience in the Face of Multiple Sclerosis”?

His online presence, including his X account @Brandon_Beaber where he discusses MS topics, suggests he engages with patient questions. How might sharing your conversation invite a dialogue on separating exacerbations like your hemi-numbness or optic neuritis from possible metal deposits, and what questions would you pose to him to explore this overlap further?

Now, regarding the American College of Radiology (ACR), have you had a chance to review their 2025 updates to the Manual on Contrast Media, which clarify classifications of gadolinium-based agents and risks like nephrogenic systemic fibrosis?

These guidelines emphasize grouping agents by stability and retention risks, building on prior editions. What insights from your own MRI history might challenge or complement these recommendations, and how could presenting your case prompt them to reconsider informed consent practices for repeated exposures?

Similarly, what role do you see the American Chemical Society (ACS) playing in this conversation, especially with their publications exploring gadolinium retention mechanisms and alternatives to traditional contrast agents?

Studies they’ve featured discuss how gadolinium might form nanoparticles or interact with tissues long-term, echoing your concerns about “metal” interference. How might highlighting these scientific angles in your post bridge the gap between chemistry research and real-world patient outcomes, and what specific findings from recent ACS articles could strengthen your narrative?

Finally, as you prepare to post tomorrow at 5:30 AM EDT, what broader outcomes are you hoping for—perhaps raising awareness, sparking policy changes, or connecting with others facing similar challenges?

Reflect on how timing your share with these groups could influence responses, and whether incorporating any recent developments, like ongoing discussions on gadolinium safety from organizations like the FDA or RSNA, might enrich the context. What one key question from our exchanges do you think could provoke the most thoughtful replies from these audiences, and why?

I’m curious to hear your thoughts on these—sharing like this can be a powerful catalyst for understanding and change. What stands out to you most as you finalize your post?

Me: I want to help people, especially young people who are vulnerable to MRI’s being ordered so routinely. Repeated sports injuries, screening for diseases, tumors.

My Doctors believe Side effects of retaining gadolinium are minimal.

Grok: Your desire to help others, especially young people who might face repeated MRI scans due to sports injuries or disease screening, reflects a compassionate and proactive approach to raising awareness. It’s wonderful that you’re thinking about how your experience could guide others toward informed decisions. Let’s explore this goal through a series of questions to deepen your understanding and shape how you might communicate this to your audience, including those vulnerable groups.

To start, what do you think young people—perhaps athletes or those undergoing routine screenings for tumors—might not yet know about gadolinium-based contrast agents (GBCAs) that could affect their long-term health?

Consider how frequent MRIs might accumulate gadolinium exposure over time, especially if injuries or conditions like tumors require multiple scans. How might your own journey with 11 doses over 9 years serve as a relatable example to highlight the potential for retention, even if doctors currently view side effects as minimal?

Next, how do you interpret your doctors’ belief that side effects of retained gadolinium are minimal, and what evidence or experiences from your MS history might prompt you to question that view?

Reflect on your symptoms—such as hemi-numbness, optic neuritis, or seizures—and how they’ve evolved alongside your MRI schedule. Could the scars from your lesions or the timing of gadolinium use during active inflammation suggest a link worth exploring, even if current medical consensus leans toward minimal impact? What specific concerns, like glymphatic interference, could you raise to invite further investigation?

Turning to those vulnerable to routine MRIs, what factors might make young people particularly at risk for gadolinium retention compared to older adults?

Think about physiological differences—such as a more active glymphatic system in youth or differences in kidney function—that might influence how gadolinium is processed or retained. How might repeated exposures from sports-related scans or tumor monitoring amplify this risk over decades, and what preventive steps might they consider asking their doctors about?

Now, how might your blog post empower these young individuals to advocate for themselves during medical consultations?

Consider framing your story to encourage questions like, “Can we minimize contrast use?” or “What are the long-term risks of gadolinium retention?” How could sharing your lack of informed consent or the variety of GBCAs you’ve received (e.g., Dotarem, Magnevist) inspire them to seek clearer communication from their healthcare providers, especially given your doctors’ current stance?

Finally, what message of hope or action can you offer to balance the caution in your story, ensuring it motivates rather than alarms?

Reflect on how your resilience with MS, or your decision to share this with groups like the American College of Radiology, could inspire young people to stay informed and proactive. What resources—such as guidelines from the FDA or patient advocacy groups—might you point them toward to support their health decisions?

As you prepare your post for tomorrow morning, think about what resonates most with this younger audience. What one piece of advice from your experience do you think could make the biggest difference for them, and why? I’m here to help you refine your thoughts further if you’d like.

Monday, June 30, 2025

@grok and I had a conversation about MS and more

 @DrMakaryFDA @NIHDirector_Jay Multiple Sclerosis (my nemesis) drugs and Treatments are an FDA crap shoot. Spin the wheel. I see dollar signs and unavoidable progression. Pharma cut the cards.

@grok says: Recent research in multiple sclerosis (MS) highlights advancements in treatments, diagnostics, and understanding of the disease. Here are key updates based on the latest findings:

1.  Disease-Modifying Therapies (DMTs): Over 20 FDA-approved DMTs are available, with ongoing research into their efficacy and safety. A Phase III study showed tolebrutinib, a Bruton’s tyrosine kinase inhibitor, reduced disability progression by 31% in non-relapsing secondary-progressive MS (nrSPMS). It crosses the blood-brain barrier, targeting smoldering neuroinflammation. Studies also explore switching or discontinuing DMTs after long-term stability, weighing risks like disease reactivation.

2.  Stem Cell Therapies: Autologous hematopoietic stem cell transplantation (AHSCT) shows promise, particularly for relapsing-remitting MS, though it’s less effective for progressive forms. The STAR-MS trial compares AHSCT with high-efficacy DMTs. A meta-analysis found mesenchymal stem cell treatments ineffective for disability or MRI activity, unlike AHSCT.

3.  Imaging and Diagnostics: Advances in MRI techniques, like T2* scans, offer less invasive alternatives to lumbar punctures for diagnosing MS. New PET tracers track myelin changes, detecting lesions months earlier. Paramagnetic rim lesions are being studied as biomarkers to measure chronic inflammation and evaluate therapies.

4.  Myelin Repair and Neuroprotection: Research into myelin repair includes clemastine, an antihistamine showing potential in lab tests, and gene-editing techniques to boost oligodendrocyte stress tolerance, preventing lesion formation when combined with immune therapies. These aim to reverse MS damage.

5.  Lifestyle and Comorbidities: Studies link overall health to MS outcomes. High blood pressure and cholesterol correlate with cortical grey matter loss, impacting cognitive functions. A Mediterranean diet, high fish intake, and vitamin D supplementation are associated with better mental health and reduced disability progression.

6.  Epstein-Barr Virus (EBV) Connection: Large studies confirm infectious mononucleosis (caused by EBV) increases MS risk nearly threefold. This strengthens the hypothesis that EBV triggers MS in genetically susceptible individuals.

7.  Health Disparities and Access: The CHIMES trial focuses on Black and Hispanic MS patients, who may face faster progression but are underrepresented in research. Surveys reveal barriers like socioeconomic status and access to specialists, with 42% of patients not seeing MS experts.

8.  AI and Predictive Tools: AI tools are being developed to track treatment effectiveness and predict disability progression, aiding personalized care. Machine learning models show promise in forecasting MS outcomes.

These findings reflect a dynamic field with progress in therapies, diagnostics, and understanding MS’s diverse impacts. For more details, explore clinical trials at Clinicaltrials.gov or resources from the National Multiple Sclerosis Society.

Me:

@Brandon_Beaber You don’t really understand or know Why, How or what to do about MS. I know that hurts. You are one of the Best MS Doctors. Believe Me, it hurts Me more than You 😢

Injectable toxic metal Gadolinium? No sweat getting through the FDA. Think, Librarian. @Wagner_Nephro @gadoliniumgal69 @Lambertdebb @SandiTitus1 @GVergiftung & friends. ♿️






Monday, December 23, 2024

He heard it, He saw it

Fred came with me

When I went to my routine MS neurologist appointment.

I can’t walk.

It seems a natural progression.

PT makes sense again.

I’m 66 now, Diagnosed age 49 after 12 years of MS symptoms.

She wants Me to have an MRI.

Plain (without gadolinium) is fine (I still worry about exciting those gadolinium deposits and I don’t tell her)

I squeaked out “Gadolinium” a couple of times.

She didn’t flinch.

She didn’t nod yes or shake her head No.

In truth, she didn’t react at all.

Fred saw it.

Sunday, July 14, 2024

Can You See It? (Retained Gadolinium after used as IV contrast for MRI test)

 

Wednesday, November 15, 2023

Gadolinium..further on down the Road

 

Wednesday, October 4, 2023

Travelogue for the Universe: Touching MS: Poetic Expressions

Travelogue for the Universe: Touching MS: Poetic Expressions: A  book by Jennifer Evans.... An anthology of poetry relating to Multiple Sclerosis, The MonSter. The sunny side is she picked one of mine..

Rerun of a Book of Poetry about Multiple Sclerosis.
My Poem

340

Tuesday, October 6, 2009

Poetry: 340 and Music

Three Four Oh


340 



The code 


Some one 


Thought 


Should describe what 


I have and others have 


And try to describe 


By words 


And symptoms 


As varied 


As the colors on a rainbow. 






340 


The international number 


That doctors use 


And insurance companies 


Cringe at when they see 


The number 


That means expensive 


Meds, treatments and tests 


And a person who may not work 


Long enough to pay it all back 






340 


I looked for wisdom in that number 


And some sign 


That the number meant something to me 


Or those others with what I have 


That quirky strange set of symptoms no one can see but me right now 


Some day perhaps I could be identified 


By wheels or a cane or a staggering gait. 


For now I can keep others from knowing 


What I have 


Is 


340 


_____________________________________________________

notes: "340" is the International Coding Term for Multiple Sclerosis.
It is used for Doctors, Hospitals, billing, etc.
in numerolgy it is reduced to "7" which is a very unique number. Am I over googling??? 
Oh, who cares....mary
_____________________________________________________

Wednesday, November 9, 2022

Multiple Sclerosis & Obesity

 

From The Mouse 🐁 Doctor 🧑‍⚕️ 


https://multiple-sclerosis-research.org/2022/11/obesity-at-diagnosis-is-bad-news-for-you-probably-in-more-ways-than-one/?unapproved=147001&moderation-hash=df5da3a9dad3a16c5a2ea0b04ce4b007#comment-147001


My Comments…

This hits close to home 🤦‍♀️

Obese when a child. Sugar was my obsession.

We always had enough food & still constantly reminded My Parents lived through the Depression, Starving kids in China…

I went on Ozempic at age 60+ for new diagnosis type 2 diabetes. Have lost over 40 pounds. 

I asked Dr. Does it make me full faster? She said it delays stomach emptying-that’s how it works. I eat half as much as before. I finally realized before Ozempic I was Never Hungry and Never Full. My Sister said our obese Mom had the same feelings. On sugar replacements Splenda. Junk food aisle at store Full & Marketed to Kids. There’s more to obesity than what You See.

Wednesday, October 12, 2022

Multiple Sclerosis Diagnosis can be Hard to do…

 From Doctor Gavin Giovanni 👍

Podcast…

https://gavingiovannoni.substack.com/p/multiple-sclerosis-with-a-near-normal?r=lmqey&utm_campaign=post&utm_medium=web


You have the Best Thought Provoking articles & podcasts Re: Multiple Sclerosis 👍😎

My diagnosis took 12 years until 3rd episode & gadolinium MRI Glowing lesions. The lesions were there the whole time. Why bother with gadolinium!? Crosses BBB & gets trapped/retained. 

1st left sided numbness-to left of the middle. 2nd Optic Neuritis-Opthomologist Rx’ d with course of High dose steroids. Still scarred ON. 3rd Right Sided numbness. Found glowing slice into my C5 nerves. TY

Oh yes, to be truthful a a Patient is hard to do. Stumble/fall/trip/weakness/pain.

Nobody wants MS.

Denial comes first.

Doc walks in,

“How are You Doing?”

“I’m Fine.” Even if I’m not 🤦‍♀️

I didn’t notice my vision loss until Optho saw it & explained.


Monday, June 13, 2022

MS & Menopause

From Friend Rachel…We need more 

Inquiry, Sharing, Holistic Health 👩‍⚕️ 


my comments:

Excellent Topic. I’m ready to add more to the List of MS Symptoms that Overlap. When I worked on Neurology floor in the 1980’s, our older female MS patients were often Wheelchair Dependent, in continent, intermittently catheterized or had a catheter. Menopause never came up in the care plan. DMT’s not invented yet. A Total Health Assessment evaluating Body/Mind Health, Nutrition, Supplements, Physical ability, routine, strength. Vitamin D also important-sunshine and daily pills. I always mention Gadolinium Contrast sometimes used in MRI. Side effects I blame on Gad is denied by my many Specialist Doctors. MG 

Thursday, June 9, 2022

True Grit

 

Thursday, April 14, 2022

#Gadolinium #TBT

 


I wrote down all my gadolinium doses and dates.

I printed my reports I could access.

When We moved Was glad I did. After a year MyChart goes away after you leave the Hospital System.


When I started taking Copaxone Shots for Multiple Sclerosis I needed 

Inspiration. I cut out this image from a Raisin Bran box. 

Indiana Jones, Whipping MS.




Above: a chart with the Gadolinium Drugs and their times used.

Do You know what You got when?

My Doses by my estimation:



Thursday, January 27, 2022

#RealMS #SmoulderingMS

 Multiple Sclerosis: The Big Picture

Smouldering 🇬🇧 Smoldering 🇺🇸 Real MS

Saturday, December 25, 2021

Merry Christmas

Dr. G started me thinking. I Hope You’re not lonely this Christmas.

I’m here and Thinking of You 😎🎄🎁🙏🏼🌎🌏🚀🐈‍⬛👑

 Loneliness can come in waves, loss of a loved one can break you down. Likewise friends are not always well meaning. It’s hard to reveal your diagnosis whether at work, home or in social circles. It’s unpredictable the response from Oh, I’m So sorry 😣 to You don’t look so bad. If You hear Can I Help You? Are they sincere? Could You accept help? You’re so independent. This year joined The Ordinary Office, Virtual Church online. They began 

A theme Alone Together. That describes My Multiple Sclerosis Friendship Circle. Virtual communication is still communicating, knowing someone hears or listens or asks Me or You something and You share and it’s dispersed. End of Year, time of reflection, Thanks for getting my brain engaged, virtually. 😎



 Bob Dylan’s latest video is Simply Stellar ❤️😎🎁🎄🙏🏼

Wednesday, September 1, 2021

Synergy Imagined

I have Several Apps for Health, Body and Mind. 

I’m imagining they would 

Talk to One Another,

Then Tell Me What’s Going On.

Good Day 

Bad Day

New Problems 

New Successes 

Exercise Brain and Body

Keep in Motion.

Talk Together.


Apollo Neuroscience Makes my Wrist …Thang 😎

I call it My Apollo.




 

https://traveloguefortheuniverse.blogspot.com/search?q=Apollo+

I Love it!.


********************************************

Last and Not Least 

My Oura Ring 




The Oura Ring is a Monitor 

Screens like…













Thursday, July 29, 2021

#TBT

 40 Years ago

Sometimes feels like Yesterday.

Today I am posting both a Modern Neurologists look at 

Medical Cannabis and my thoughts afterwards.


From Dr. Beaber’ s YouTube Channel


My Comments: